Literature DB >> 2155639

The acute toxic effect of the phosphodiesterase inhibitor rolipram on plasma osmolality.

I Sturgess, G F Searle.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2155639      PMCID： PMC1380141          DOI： 10.1111/j.1365-2125.1990.tb03651.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  5 in total

Review 1.  A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity.

Authors:  R E Weishaar; M H Cain; J A Bristol
Journal:  J Med Chem       Date:  1985-05       Impact factor: 7.446

2.  Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta.

Authors:  C Lugnier; P Schoeffter; A Le Bec; E Strouthou; J C Stoclet
Journal:  Biochem Pharmacol       Date:  1986-05-15       Impact factor: 5.858

3.  Urinary adenosine 3',5'-monophosphate (cAMP) response to antidiuretic hormone in diabetes insipidus (DI): comparison between congenital nephrogenic DI type 1 and 2, and vasopressin sensitive DI.

Authors:  T Ohzeki
Journal:  Acta Endocrinol (Copenh)       Date:  1985-04

4.  Results of a phase II study of the antidepressant effect of rolipram.

Authors:  E Zeller; H J Stief; B Pflug; M Sastre-y-Hernández
Journal:  Pharmacopsychiatry       Date:  1984-11       Impact factor: 5.788

5.  Comparative hemodynamic and hormonal response of enoximone and dobutamine in severe congestive heart failure.

Authors:  B F Uretsky; T Generalovich; J G Verbalis; A M Valdes; P S Reddy
Journal:  Am J Cardiol       Date:  1986-07-01       Impact factor: 2.778
  5 in total
  4 in total

Review 1.  Phosphodiesterase inhibitors: new opportunities for the treatment of asthma.

Authors:  T J Torphy; B J Undem
Journal:  Thorax       Date:  1991-07       Impact factor: 9.139

2.  Osthole pretreatment alleviates TNBS-induced colitis in mice via both cAMP/PKA-dependent and independent pathways.

Authors:  Wu Sun; Yun Cai; Xin-Xin Zhang; Hao Chen; Yan-Die Lin; Hao Li
Journal:  Acta Pharmacol Sin       Date:  2017-06-12       Impact factor: 6.150

Review 3.  Cyclic nucleotide phosphodiesterases in the human lung.

Authors:  G Dent; H Magnussen; K F Rabe
Journal:  Lung       Date:  1994       Impact factor: 2.584

4.  The selective phosphodiesterase 4 inhibitor roflumilast and phosphodiesterase 3/4 inhibitor pumafentrine reduce clinical score and TNF expression in experimental colitis in mice.

Authors:  Florian Rieder; Britta Siegmund; Daniela S Bundschuh; Hans-Anton Lehr; Stefan Endres; Andreas Eigler
Journal:  PLoS One       Date:  2013-02-28       Impact factor: 3.240
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.